TGen's Dr. Daniel Von Hoff delivers first Lori Groetken Memorial Lecture

October 04, 2012

PHOENIX, Ariz. -- Oct. 4, 2012 -- Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute (TGen), is the first recipient of the Lori Groetken Memorial Lecture and Award.

Dr. Von Hoff's lecture, "A Relentless Molecular Pursuit Approach to Take Out Pancreatic Cancer," is at noon Oct. 5 at the Siteman Cancer Center at Washington University in St. Louis.

"I am extremely honored and humbled to be the first recipient of the Lori Groetken Memorial Lecture, and I look forward to the opportunity to present this lecture and discuss how we can make advances together against this terrible cancer," said Dr. Von Hoff.

The lecture and award is in memory of Lori Groetken, a pancreatic cancer patient who fought the disease for two years. She and her husband, Cecil, were at the forefront of raising funds for pancreatic cancer research at the Siteman Cancer Center. The annual lecture series in her name has been created to recognize individuals whose research makes substantial contributions to the field of pancreatic cancer research.

"In light of your significant contributions in leading the world efforts in genomic research and novel therapy development in pancreatic cancer research, you have been selected to be the inaugural recipient for the Lori (Groetken) Memorial Lectureship," according to a letter to Dr. Von Hoff from Dr. Andrea Wang-Gillam, Assistant Professor in the Division of Oncology, Section of Medical Oncology, at Washington University.

Dr. Von Hoff, M.D., F.A.C.P., is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He also is the Chief Scientific Officer of TGen's clinical trials at Scottsdale Healthcare's Virginia G. Piper Cancer Center, Chief Scientific Officer at US Oncology, Professor of Medicine at Mayo Clinic, and Clinical Professor of Medicine at the University of Arizona College of Medicine.

A book published this year -- The Creative Destruction of Medicine by Dr. Eric Topol, Director of the Scripps Translational Science Institute -- describes Dr. Von Hoff as the nation's "leading authority on pancreatic cancer."

In 2010, Dr. Von Hoff won a top award from the American Society of Clinical Oncology (ASCO) for his cancer research. He received the David A. Karnofsky Memorial Award and Lecture at ASCO's 46th Annual Meeting "for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer."

Dr. Von Hoff is the Co-Team Leader for the Stand Up To Cancer (SU2C) Pancreatic Cancer "Dream Team," in which he leads a team investigating how to cut off the fuel supply of nutrients to pancreatic cancer cells.

Dr. Von Hoff founded the Pancreatic Cancer Research Team (PCRT), an international network of clinical trials sites organized under TGen Drug Development (TD2), a TGen subsidiary. PCRT represents a consortium of 45 highly experienced investigators and clinics from across the U.S. and Europe, dedicated to finding a cure for pancreatic cancer, which annually kills more than 37,000 people in the U.S., and is the nation's 4th leading cause of cancer death.
About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit:

Press Contact:
Steve Yozwiak
TGen Senior Science Writer

The Translational Genomics Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to